It is time to end our love affair with short-acting β2-agonists in asthma

Michael G Crooks; Shoaib Faruqi

doi:10.1183/23120541.00353-2022

It is time to end our love affair with short-acting β₂-agonists in asthma

ERJ Open Res. 2022 Oct 17;8(4):00353-2022. doi: 10.1183/23120541.00353-2022. eCollection 2022 Oct.

Authors

Michael G Crooks^{1

2}, Shoaib Faruqi²

Affiliations

¹ Respiratory Research Group, Hull York Medical School, University of Hull, Kingston upon Hull, UK.
² Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UK.

Abstract

In this issue of ERJOR, Noorduynet al. add data to the growing literature showing that SABA overuse in asthma is both common and associated with severe exacerbations. It is time to take note and act to tackle this global issue. https://bit.ly/3BfwhfS.

Publication types

Editorial